After finishing at $16.34 in the prior trading day, Oscar Health Inc (NYSE: OSCR) closed at $16.75, up 2.51%. In other words, the price has increased by $+0.41 from its previous closing price. On the day, 1889714 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of OSCR by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on November 02, 2023, Upgraded its rating to Buy and sets its target price to $9 from $8 previously.
On June 06, 2023, BofA Securities Upgraded its rating to Neutral which previously was Underperform and also upped its target price recommendation from $5.40 to $8.75.
Wells Fargo Upgraded its Equal Weight to Overweight on November 16, 2022, while the target price for the stock was maintained at $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 when Quane Alessandrea C. sold 55,000 shares for $18.02 per share. The transaction valued at 991,100 led to the insider holds 169,366 shares of the business.
Bopitiya Ranmali sold 42,865 shares of OSCR for $772,856 on Feb 16. The EVP & Chief Legal Officer now owns 87,818 shares after completing the transaction at $18.03 per share. On Dec 06, another insider, Blackley Richard Scott, who serves as the Chief Financial Officer of the company, sold 30,029 shares for $8.16 each. As a result, the insider received 245,037 and left with 548,613 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 3.85B and an Enterprise Value of 2.28B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.66 while its Price-to-Book (P/B) ratio in mrq is 4.78. Its current Enterprise Value per Revenue stands at 0.39.
Stock Price History:
Over the past 52 weeks, OSCR has reached a high of $18.55, while it has fallen to a 52-week low of $3.22. The 50-Day Moving Average of the stock is 11.88, while the 200-Day Moving Average is calculated to be 8.27.
Shares Statistics:
The stock has traded on average 2.98M shares per day over the past 3-months and 3.99M shares per day over the last 10 days, according to various share statistics. A total of 193.87M shares are outstanding, with a floating share count of 144.49M. Insiders hold about 37.10% of the company’s shares, while institutions hold 45.78% stake in the company. Shares short for OSCR as of Jan 31, 2024 were 6.33M with a Short Ratio of 2.12, compared to 4.47M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.76% and a Short% of Float of 3.87%.
Earnings Estimates
Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of $0.27 for the current quarter, with a high estimate of $0.33 and a low estimate of $0.22, while EPS last year was -$0.18. The consensus estimate for the next quarter is $0.19, with high estimates of $0.27 and low estimates of $0.15.
Analysts are recommending an EPS of between -$0.07 and -$0.17 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is $0.42, with 4 analysts recommending between $0.57 and $0.3.
Revenue Estimates
2 analysts predict $2.04B in revenue for the current quarter. It ranges from a high estimate of $2.05B to a low estimate of $2.03B. As of the current estimate, Oscar Health Inc’s year-ago sales were $1.15B, an estimated increase of 77.80% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $2.06B, an increase of 35.70% less than the figure of $77.80% in the same quarter last year. There is a high estimate of $2.08B for the next quarter, whereas the lowest estimate is $2.05B.
A total of 2 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $8.38B, while the lowest revenue estimate was $8.25B, resulting in an average revenue estimate of $8.32B. In the same quarter a year ago, actual revenue was $5.86B, up 41.90% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $9.42B in the next fiscal year. The high estimate is $9.59B and the low estimate is $9.25B. The average revenue growth estimate for next year is up 13.20% from the average revenue estimate for this year.
